ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 15

TKI Monotherapy Data in Non–Clear Cell RCC

, , , ,

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

EP. 1: First-Line Treatments for Advanced Clear Cell RCC
EP. 2: Long-Term Follow-Up from CheckMate 214 in Advanced RCC
EP. 3: CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC
EP. 4: Recent Subgroup Analyses from the CLEAR study in Advanced RCC
EP. 5: LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis
EP. 6: Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC
EP. 7: CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC
EP. 8: Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC
EP. 9: LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research
EP. 10: Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC
EP. 11: CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC
EP. 12: Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC
EP. 13: Clinical Insights on Belzutifan in Advanced RCC
EP. 14: Overview of Non–Clear Cell RCC
Now Viewing
EP. 15: TKI Monotherapy Data in Non–Clear Cell RCC
EP. 16: KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC
EP. 17: Nivolumab Plus Cabozantinib in Non–Clear Cell RCC
EP. 18: Future Perspectives and Unmet Needs in Renal Cell Carcinoma

Related Content:

ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell CarcinomaSarah Cannon Research InstituteMemorial Sloan Kettering Cancer Center Yale Cancer CenterGenitourinary CancersOncLive Peer Exchange®
Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi
Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease
Understanding Graft-VS-Host Disease (GVHD) Basics